Both semaglutide and tirzepatide are glycemic controlling medications

Chemical & Physical Properties Toxicological Information CHEMICAL IDENTIFICATION RTECS NUMBER : MC0556000 CHEMICAL NAME : Glycine, N-(N-L-gamma-glutamyl-L-cysteinyl)- CAS REGISTRY NUMBER : 70-18-8 LAST UPDATED : 199710 DATA ITEMS CITED : 20 MOLECULAR FORMULA : C10-H17-N3-O6-S MOLECULAR WEIGHT : 307.36 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4020 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2238 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1250 mg/kg SEX/DURATION : female 1-22 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g
.png.jpg)
In a glovebox, 3-PBLG (1.0 g) was completely dissolved in anhydrous DCM (100 ml) in a round bottom flask at room temperarture
The discontinuation was driven by (Bergam, 2025) (Figure 2): the availability of newer, safer & more accurate alternative testing for MG including electrophysiological & antibody tests, as well as safety concerns (bradycardia & respiratory complications) limited diagnostic reliability (with both false-positive and false-negative results) The decision to remove edrophonium as an available (alternative) diagnostic test has been challenged (Keritam et al, 2026)
The World Anti-Doping Agency (WADA) maintains and updates this document annually to address emerging threats to the integrity of athletic competition